SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03941782
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This is a compassionate use protocol of BYL719 (alpelisib) treatment for a single patient
with locally advanced lymphangioma positive PI3K alpha H1047R mutation.
NCT03941782 Lymphangioma
1 Interventions
Name: Alpelisib
Description: As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
Type: Drug
There is one SNP
SNPs
Compassionate Use of BYL 719 Alpelisib
This is a compassionate use protocol of BYL719 (alpelisib) treatment for a single patient
with locally advanced lymphangioma positive PI3K alpha H1047R mutation. --- H1047R ---
HPO Nodes